

Dermatology Therapeutics Market to 2018

Novel Biologics Targeting Interleukin-17 Receptor Presents New Options in Psoriasis Treatment



GBI Research Report Guidance

The objective of updating GBI Research's coverage is to ensure that it represents the most up-to-date analysis of the industry. Changes to the industry taxonomy are built on the basis of company, association and competitor sources.


- Chapter two summarizes the introduction of the report.
- Chapter three gives an overview of the dermatology therapeutics market, its trends and the recent developments in the seven major markets.
- Chapter four estimates the market size of the US, the UK, France, Germany, Spain, Italy and Japan. The dermatology market sizes for these seven countries are estimated and forecasts to 2017 are given. A key analysis of the treatment usage pattern is also discussed.
- Chapter five covers the revenues until 2017 for the dermatological conditions covered in the report. It also analyzes the market revenues of the top seven countries individually with respect to each indication, and the branded and generic shares in 2010 and 2017. GBI Research analyzed the current landscape of the market, focusing on the key drivers and restraints influencing the markets for the different indications. The treatment flow algorithm and treatment usage pattern have been given along with the key trends from 2002 to 2017.
- Chapter six gives details on the current pipeline analysis of the dermatological disorders market. The section also contains a detailed analysis of the most promising pipeline products.
- Chapter seven analyzes the top companies operating in the dermatological disorders market. It includes benchmarking and detailed profiles of the top six companies operating in the dermatology markets on the basis of sales value.
- Chapter eight discusses in detail the strategic consolidations that have taken place within the global dermatology therapeutics market. A look into key licensing agreements is also given, with increasing focus on geographies.

Executive Summary

GBI Research has found that the global dermatology therapeutics market is one of the more mature therapeutic markets in the pharmaceutical industry. Market revenue is only expected to increase moderately due to various restraints such as generic substitutions and the availability of alternative therapies such as surgery, phototherapy and natural Over-the-Counter (OTC) medications. Nevertheless, the global dermatology therapeutics market is an attractive market for larger pharmaceutical companies.

The Dermatology Therapeutics Market is Forecast to Grow at a CAGR of XX% from 2011 to 2018

Psoriasis and acne are the most potential segments with over \$XX billion in sales in 2011 and a strong, promising pipeline



The global dermatology therapeutics market for psoriasis, acne, rosacea, atopic dermatitis, herpes and alopecia covers the top seven established markets in the world: the US, Germany, France, Spain, the UK, Italy and Japan, and was estimated to be worth \$XX billion in 2011. The market grew at a Compound Annual Growth Rate (CAGR) of XX% from 2004 to 2011. The market is expected to reach \$XX billion by 2018 at a CAGR of XX%.

Psoriasis and acne have the most potential in the global dermatological disorders market, with over \$XX billion in sales in 2011 and strong pipelines that include some promising molecules.

From 2004 to 2011, the global dermatology therapeutics market grew at a significant rate due to sales from major marketed products such as Propecia (finasteride) and finasteride-minoxidil combination products for the treatment of alopecia; Valtrex (valacyclovir hydrochloride), Zovirax (acyclovir), Famvir (famciclovir) and Zostavax (live zoster vaccine) for the treatment of herpes; Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept) and Stelara (ustekinumab) for the treatment of psoriasis; Solodyn (minocycline), Ziana gel (clindamycin phosphate XX% and tretinoin XX%), Doryx (doxycycline hyclate) and Duac topical gel (clindamycin XX% and benzoyl peroxide XX%) for the treatment of acne; Oracea (doxycycline) for the treatment of rosacea; and Protopic (tacrolimus), Elidel (pimecrolimus) and Medrol (methylprednisolone) for the treatment of atopic dermatitis.

1 Table of Contents

| | | |
|-------|--|----|
| 1 | Table of Contents..... | 7 |
| 1.1 | List of Tables..... | 11 |
| 1.2 | List of Figures..... | 13 |
| 2 | Dermatology Therapeutics Market to 2018 - Introduction..... | 15 |
| 3 | Dermatology Therapeutics Market to 2018 - Market Overview | 16 |
| 3.1 | Revenue | 16 |
| 3.2 | Annual Cost of Treatment | 17 |
| 3.3 | Treatment Usage Pattern..... | 18 |
| 3.3.1 | <i>Diseased Population</i> | 19 |
| 3.3.2 | <i>Treatment-Seeking Population</i> | 19 |
| 3.3.3 | <i>Diagnosed Population</i> | 19 |
| 3.3.4 | <i>Prescription Population</i> | 19 |
| 3.4 | Recently Approved Product..... | 19 |
| 3.4.1 | <i>Fabior (Tazarotene)</i> | 19 |
| 3.5 | Key Trends..... | 20 |
| 3.5.1 | <i>Potential New Treatment for Skin Diseases</i> | 20 |
| 3.5.2 | <i>Innovative Medicines Initiative Launched in Europe to Address Antibiotic Resistance</i> | 20 |
| 4 | Dermatology Therapeutics Market to 2018 - Geographical Landscape..... | 21 |
| 4.1 | Revenue by Country..... | 21 |
| 4.2 | The US..... | 23 |
| 4.2.1 | <i>Revenue</i> | 23 |
| 4.2.2 | <i>Annual Cost of Treatment</i> | 24 |
| 4.2.3 | <i>Treatment Usage Pattern</i> | 25 |
| 4.3 | Top Five Countries in Europe..... | 26 |
| 4.3.1 | <i>Revenue</i> | 26 |
| 4.3.2 | <i>Annual Cost of Treatment</i> | 29 |
| 4.3.3 | <i>Treatment Usage Pattern</i> | 30 |
| 4.4 | Japan..... | 32 |
| 4.4.1 | <i>Revenue</i> | 32 |
| 4.4.2 | <i>Annual Cost of Treatment</i> | 33 |
| 4.4.3 | <i>Treatment Usage Pattern</i> | 34 |
| 5 | Dermatology Therapeutics Market to 2018 - Therapeutic Landscape..... | 36 |
| 5.1 | Global Alopecia Therapeutics Market | 36 |
| 5.1.1 | <i>Introduction</i> | 36 |
| 5.1.2 | <i>Revenue</i> | 37 |
| 5.1.3 | <i>Annual Cost of Treatment</i> | 41 |
| 5.1.4 | <i>Treatment Usage Pattern</i> | 42 |
| 5.1.5 | <i>Treatment Algorithm</i> | 43 |
| 5.1.6 | <i>Drivers and Restraints</i> | 44 |
| 5.2 | Global Herpes Therapeutics Market | 45 |
| 5.2.1 | <i>Introduction</i> | 45 |
| 5.2.2 | <i>Revenue</i> | 48 |
| 5.2.3 | <i>Annual Cost of Treatment</i> | 52 |
| 5.2.4 | <i>Treatment Usage Pattern</i> | 53 |
| 5.2.5 | <i>Treatment Algorithm</i> | 55 |
| 5.2.6 | <i>Drivers and Restraints</i> | 56 |
| 5.3 | Global Psoriasis Therapeutics Market | 57 |
| 5.3.1 | <i>Introduction</i> | 57 |
| 5.3.2 | <i>Revenue</i> | 58 |
| 5.3.3 | <i>Annual Cost of Treatment</i> | 63 |

| | | |
|-------|---|-----|
| 5.3.4 | Treatment Usage Pattern..... | 64 |
| 5.3.5 | Treatment Algorithm..... | 66 |
| 5.3.6 | Drivers and Restraints..... | 67 |
| 5.4 | Global Acne Therapeutics Market..... | 68 |
| 5.4.1 | Introduction..... | 68 |
| 5.4.2 | Revenue..... | 69 |
| 5.4.3 | Annual Cost of Treatment..... | 73 |
| 5.4.4 | Treatment Usage Pattern..... | 74 |
| 5.4.5 | Treatment Algorithm..... | 76 |
| 5.4.6 | Drivers and Restraints..... | 77 |
| 5.5 | Global Rosacea Disease Therapeutics Market..... | 78 |
| 5.5.1 | Introduction..... | 78 |
| 5.5.2 | Revenue..... | 79 |
| 5.5.3 | Annual Cost of Treatment..... | 82 |
| 5.5.4 | Treatment Usage Pattern..... | 83 |
| 5.5.5 | Treatment Algorithm..... | 85 |
| 5.5.6 | Drivers and Restraints..... | 86 |
| 5.6 | Global Atopic Dermatitis Therapeutics Market..... | 87 |
| 5.6.1 | Introduction..... | 87 |
| 5.6.2 | Revenue..... | 87 |
| 5.6.3 | Annual Cost of Treatment..... | 91 |
| 5.6.4 | Treatment Usage Pattern..... | 92 |
| 5.6.5 | Treatment Algorithm..... | 94 |
| 5.6.6 | Drivers and Restraints..... | 95 |
| 6 | Dermatological Therapeutics Market - Asia-Pacific Countries..... | 97 |
| 6.1 | India..... | 97 |
| 6.1.1 | Healthcare Overview..... | 97 |
| 6.1.2 | Regulatory Landscape..... | 97 |
| 6.1.3 | Market Overview..... | 99 |
| 6.1.4 | Key Trends..... | 100 |
| 6.1.5 | Company Analysis..... | 101 |
| 6.1.6 | Drivers and Restraints..... | 104 |
| 6.2 | China..... | 105 |
| 6.2.1 | Market Overview..... | 105 |
| 6.2.2 | Key Trends..... | 105 |
| 6.3 | Australia..... | 106 |
| 6.3.1 | Market Overview..... | 106 |
| 6.3.2 | Pricing and Reimbursement..... | 107 |
| 7 | Dermatological Therapeutics Market to 2018 - Pipeline Analysis..... | 109 |
| 7.1 | Introduction..... | 109 |
| 7.1.1 | Research and Development Pipeline - Alopecia..... | 111 |
| 7.1.2 | Research and Development Pipeline - Herpes..... | 112 |
| 7.1.3 | Research and Development Pipeline - Psoriasis..... | 113 |
| 7.1.4 | Research and Development Pipeline - Acne vulgaris..... | 116 |
| 7.1.5 | Research and Development Pipeline - Rosacea..... | 117 |
| 7.1.6 | Research and Development Pipeline - Atopic Dermatitis..... | 118 |
| 7.2 | Key R&D Trends..... | 118 |
| 7.3 | Promising Molecules - NDA Filed..... | 119 |
| 7.3.1 | LAS 41002..... | 119 |
| 7.3.2 | Low-Dose Duac..... | 120 |
| 7.3.3 | Acnex..... | 121 |
| 7.4 | Promising Molecules - Phase III..... | 122 |

| | | |
|--------|---|-----|
| 7.4.1 | Zoster | 122 |
| 7.4.2 | ARYS-01 | 122 |
| 7.4.3 | V212 | 124 |
| 7.4.4 | CC-10004 | 125 |
| 7.4.5 | CD07805/47 | 126 |
| 7.5 | Promising Molecules - Phase II | 126 |
| 7.5.1 | EPB-348 | 126 |
| 7.5.2 | AMG 827 | 127 |
| 7.5.3 | V-101 | 128 |
| 7.5.4 | MK-3222 | 129 |
| 8 | Dermatology Therapeutics Market to 2018 - Competitive Landscape | 130 |
| 8.1 | Market Share Analysis: Dermatological Disorders | 130 |
| 8.2 | Competitive Profiling | 133 |
| 8.2.1 | Johnson & Johnson | 133 |
| 8.2.2 | Amgen | 135 |
| 8.2.3 | Merck & Co | 137 |
| 8.2.4 | Abbott Laboratories | 138 |
| 8.2.5 | Pfizer | 140 |
| 8.2.6 | GlaxoSmithKline | 142 |
| 8.2.7 | Novartis | 144 |
| 8.2.8 | Medicis | 146 |
| 8.2.9 | Galderma | 148 |
| 9 | Dermatology Therapeutics Market to 2018 - Deals Analysis | 151 |
| 9.1 | Mergers and Acquisitions | 151 |
| 9.1.1 | Mergers and Acquisitions by Indication | 151 |
| 9.1.2 | Mergers and Acquisitions by Type | 153 |
| 9.1.3 | Mergers and Acquisitions by Value | 153 |
| 9.1.4 | Mergers and Acquisitions by Geography | 154 |
| 9.1.5 | Major Mergers and Acquisitions Deals | 155 |
| 9.2 | Licensing Agreements | 156 |
| 9.2.1 | Licensing Agreements by Indication | 156 |
| 9.2.2 | Licensing Agreements by Year | 157 |
| 9.2.3 | Licensing Agreements by Value | 158 |
| 9.2.4 | Licensing Agreements by Geography | 159 |
| 9.2.5 | Major Licensing Agreements | 159 |
| 10 | Aesthetic Dermatology | 161 |
| 10.1 | Introduction | 161 |
| 10.2 | Drivers and Restraints | 163 |
| 10.2.1 | Drivers | 163 |
| 10.2.2 | Restraints | 164 |
| 10.3 | Botulinum Toxin | 164 |
| 10.3.1 | Major Marketed Products | 164 |
| 10.3.2 | Most Promising Molecules | 165 |
| 10.4 | Dermal Fillers | 166 |
| 10.4.1 | Temporary Biodegradable Fillers | 166 |
| 10.4.2 | Semi-Permanent Biodegradable Fillers | 167 |
| 10.5 | Breast Augmentation | 167 |
| 10.5.1 | Style 410 | 167 |
| 10.5.2 | Breast Implants Linked to Lymphoma Risk | 167 |
| 11 | Dermatology Therapeutics Market to 2017 - Appendix | 168 |
| 11.1 | Market Definitions | 168 |
| 11.2 | Abbreviations | 168 |

| | | |
|--------|-------------------------------|-----|
| 11.3 | Bibliography | 170 |
| 11.4 | Research Methodology | 172 |
| 11.4.1 | Coverage | 172 |
| 11.4.2 | Secondary Research | 172 |
| 11.4.3 | Primary Research | 173 |
| 11.5 | Therapeutic Landscape | 173 |
| 11.5.2 | Market Size by Geography..... | 175 |
| 11.6 | Geographical Landscape | 176 |
| 11.7 | Pipeline Analysis | 176 |
| 11.8 | Competitive Landscape | 176 |
| 11.8.1 | Expert Panel Validation | 176 |
| 11.9 | Contact Us..... | 176 |
| 11.10 | Disclaimer..... | 177 |

1.1 List of Tables

| | | |
|-----------|---|----|
| Table 1: | Dermatology Therapeutics Market, Global, Revenue (\$bn), 2004-2011 | 16 |
| Table 2: | Dermatology Therapeutics Market, Global, Revenue Forecasts (\$bn), 2011-2018 | 16 |
| Table 3: | Dermatology Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2011 | 17 |
| Table 4: | Dermatology Therapeutics Market, Global, Annual Cost of Treatment (\$), 2011-2018 | 17 |
| Table 5: | Dermatology Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011 | 18 |
| Table 6: | Dermatology Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018 | 18 |
| Table 7: | Dermatology Therapeutics Market, Revenue by Geography (\$bn), 2004-2011 | 21 |
| Table 8: | Dermatology Therapeutics Market, Revenue Forecasts by Geography (\$bn), 2011-2018 | 22 |
| Table 9: | Dermatology Therapeutics Market, the US, Revenue (\$bn), 2004-2011 | 23 |
| Table 10: | Dermatology Therapeutics Market, The US, Revenue Forecasts (\$bn), 2011-2018 | 23 |
| Table 11: | Dermatology Therapeutics Market, The US, Annual Cost of Treatment (\$), 2004-2011 | 24 |
| Table 12: | Dermatology Therapeutics Market, The US, Annual Cost of Treatment (\$), 2011-2018 | 24 |
| Table 13: | Dermatology Therapeutics Market, the US, Treatment Usage Pattern (million), 2004-2011 | 25 |
| Table 14: | Dermatology Therapeutics Market, the US, Treatment Usage Pattern (million), 2011-2018 | 25 |
| Table 15: | Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue (\$m), 2004-2011 | 27 |
| Table 16: | Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue Forecasts (\$m), 2011-2018 | 27 |
| Table 17: | Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue by Country (\$bn), 2004-2011 | 28 |
| Table 18: | Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue Forecasts by Country (\$bn), 2011-2018 | 28 |
| Table 19: | Dermatology Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment (\$), 2004-2011 | 29 |
| Table 20: | Dermatology Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment (\$), 2011-2018 | 29 |
| Table 21: | Dermatology Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2004-2011 | 30 |
| Table 22: | Dermatology Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2011-2018 | 31 |
| Table 23: | Dermatology Therapeutics Market, Japan, Revenue (\$bn), 2004-2011 | 32 |
| Table 24: | Dermatology Therapeutics Market, Japan, Revenue Forecasts (\$bn), 2011-2018 | 32 |
| Table 25: | Dermatology Therapeutics Market, Japan, Annual Cost of Treatment (\$), 2004-2011 | 33 |
| Table 26: | Dermatology Therapeutics Market, Japan, Annual Cost of Treatment (\$), 2011-2018 | 33 |
| Table 27: | Dermatology Therapeutics Market, Japan, Treatment Usage Pattern (million), 2004-2011 | 34 |
| Table 28: | Dermatology Therapeutics Market, Japan, Treatment Usage Pattern (million), 2011-2018 | 34 |
| Table 29: | Alopecia Therapeutics Market, Global, Revenue (\$bn), 2004-2011 | 38 |
| Table 30: | Alopecia Therapeutics Market, Global, Revenue Forecasts (\$bn), 2011-2018 | 38 |
| Table 31: | Alopecia Therapeutics Market, Global, Revenue by Geography (\$m), 2004-2011 | 39 |
| Table 32: | Alopecia Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2011-2018 | 40 |
| Table 33: | Alopecia Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2011 | 41 |
| Table 34: | Alopecia Therapeutics Market, Global, Annual Cost of Treatment (\$), 2011-2018 | 41 |
| Table 35: | Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011 | 42 |
| Table 36: | Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018 | 42 |
| Table 37: | Herpes Therapeutics Market, Global, Revenue (\$bn), 2004-2011 | 48 |
| Table 38: | Herpes Therapeutics Market, Global, Revenue Forecasts (\$bn), 2011-2018 | 48 |
| Table 39: | Herpes Therapeutics Market, Global, Revenue by Geography (\$m), 2004-2011 | 50 |
| Table 40: | Herpes Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2011-2018 | 50 |
| Table 41: | Herpes Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2011 | 52 |
| Table 42: | Herpes Therapeutics Market, Global, Annual Cost of Treatment (\$), 2011-2018 | 52 |
| Table 43: | Herpes Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011 | 53 |
| Table 44: | Herpes Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018 | 53 |
| Table 45: | Psoriasis Therapeutics Market, Global, Revenues (\$bn), 2004-2011 | 58 |
| Table 46: | Psoriasis Therapeutics Market, Global, Revenue Forecasts (\$bn), 2011-2018 | 59 |
| Table 47: | Psoriasis Therapeutics Market, Global, Marketed Products, 2012 | 59 |
| Table 48: | Psoriasis Therapeutics Market, Global, Revenue by Geography (\$m), 2004-2011 | 61 |
| Table 49: | Psoriasis Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2011-2018 | 61 |
| Table 50: | Psoriasis Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2011 | 63 |

| | | |
|-----------|---|-----|
| Table 51: | Psoriasis Therapeutics Market, Global, Annual Cost of Treatment (\$), 2011-2018 | 63 |
| Table 52: | Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011 | 65 |
| Table 53: | Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011 | 65 |
| Table 54: | Acne Therapeutics Market, Global, Revenue (\$bn), 2004-2011..... | 69 |
| Table 55: | Acne Therapeutics Market, Global, Revenue Forecasts (\$bn), 2011-2018 | 69 |
| Table 56: | Acne Therapeutics Market, Global, Revenue by Geography (\$m), 2004-2011 | 71 |
| Table 57: | Acne Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2011-2018 | 72 |
| Table 58: | Acne Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2011..... | 73 |
| Table 59: | Acne Therapeutics Market, Global, Annual Cost of Treatment (\$), 2011-2018..... | 73 |
| Table 60: | Acne Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011..... | 74 |
| Table 61: | Acne Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018..... | 75 |
| Table 62: | Rosacea Therapeutics Market, Global, Revenue (\$bn), 2004-2011..... | 79 |
| Table 63: | Rosacea Therapeutics Market, Global, Revenue Forecasts (\$bn), 2011-2018 | 79 |
| Table 64: | Rosacea Therapeutics Market, Global, Revenue by Geography (\$m), 2004-2011..... | 80 |
| Table 65: | Rosacea Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2011-2018 | 81 |
| Table 66: | Rosacea Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2011..... | 82 |
| Table 67: | Rosacea Therapeutics Market, Global, Annual Cost of Treatment (\$), 2011-2018..... | 82 |
| Table 68: | Rosacea Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011..... | 83 |
| Table 69: | Rosacea Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018..... | 84 |
| Table 70: | Atopic Dermatitis Therapeutics Market, Global, Revenue (\$m), 2004-2011..... | 88 |
| Table 71: | Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts (\$m), 2011-2018 | 88 |
| Table 72: | Atopic Dermatitis Therapeutics Market, Global, Revenue by Geography (\$m), 2004-2011 | 89 |
| Table 73: | Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2011-2018..... | 90 |
| Table 74: | Atopic Dermatitis Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2011..... | 91 |
| Table 75: | Atopic Dermatitis Therapeutics Market, Global, Annual Cost of Treatment (\$), 2011-2018..... | 91 |
| Table 76: | Atopic Dermatitis Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011..... | 92 |
| Table 77: | Atopic Dermatitis Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018..... | 93 |
| Table 78: | Dermatology Therapeutics Market to 2018, NLEM, Dermatological Medicines Topical, India, 2011 | 99 |
| Table 79: | Dermatology Therapeutics Market to 2018, Marketed Products, Glenmark, India, 2012 | 102 |
| Table 80: | Dermatology Therapeutics Market to 2018, Marketed Products, Galderma, India, 2012 | 103 |
| Table 81: | Dermatology Therapeutics Market to 2018, Major Marketed Products, Australia, 2012..... | 106 |
| Table 82: | Dermatology Therapeutics Market to 2018, PBS Reimbursement List, Australia, 2012 | 107 |
| Table 83: | Dermatology Therapeutics Market, Global, Other Manufacturers, 2011 | 131 |

1.2 List of Figures

| | | |
|------------|---|----|
| Figure 1: | Dermatology Therapeutics Market, Global, Revenue Forecasts (\$bn), 2004-2018 | 16 |
| Figure 2: | Dermatology Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2018 | 17 |
| Figure 3: | Dermatology Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018 | 18 |
| Figure 4: | Dermatology Therapeutics Market, Revenue Forecasts by Geography (\$bn), 2004-2018 | 21 |
| Figure 5: | Dermatology Therapeutics Market, the US, Revenue Forecasts (\$bn), 2004-2018 | 23 |
| Figure 6: | Dermatology Therapeutics Market, the US, Annual Cost of Treatment (\$), 2004-2018 | 24 |
| Figure 7: | Dermatology Therapeutics Market, the US, Treatment Usage Pattern (million), 2004-2018 | 25 |
| Figure 8: | Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue Forecasts (\$bn), 2004-2018 | 26 |
| Figure 9: | Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue Forecasts by Country (\$bn), 2004-2018 | 27 |
| Figure 10: | Dermatology Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment (\$), 2004-2018 | 29 |
| Figure 11: | Dermatology Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2004-2018 | 30 |
| Figure 12: | Dermatology Therapeutics Market, Japan, Revenue Forecasts (\$bn), 2004-2018 | 32 |
| Figure 13: | Dermatology Therapeutics Market, Japan, Annual Cost of Treatment (\$), 2004-2018 | 33 |
| Figure 14: | Dermatology Therapeutics Market, Japan, Treatment Usage Pattern (million), 2004-2018 | 34 |
| Figure 15: | Alopecia Therapeutics Market, Global, Revenue Forecasts (\$bn), 2004-2018 | 37 |
| Figure 16: | Alopecia Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2004-2018 | 39 |
| Figure 17: | Alopecia Therapeutics Market, Global, Revenue Segmentation (%), 2011 and 2018 | 40 |
| Figure 18: | Alopecia Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2018 | 41 |
| Figure 19: | Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018 | 42 |
| Figure 20: | Alopecia Therapeutics Market, Global, Treatment Algorithm | 43 |
| Figure 21: | Alopecia Therapeutics Market, Drivers and Restraints, 2012 | 44 |
| Figure 22: | Herpes Therapeutics Market, Global, Revenue Forecasts (\$bn), 2004-2018 | 48 |
| Figure 23: | Herpes Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2004-2018 | 49 |
| Figure 24: | Herpes Therapeutics Market, Global, Revenue Segmentation (%), 2011 and 2018 | 51 |
| Figure 25: | Herpes Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2018 | 52 |
| Figure 26: | Herpes Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018 | 53 |
| Figure 27: | Herpes Therapeutics Market, Global, Treatment Algorithm | 55 |
| Figure 28: | Herpes Therapeutics Market, Drivers and Restraints, 2012 | 56 |
| Figure 29: | Psoriasis Therapeutics Market, Global, Revenue Forecasts (\$bn), 2004-2018 | 58 |
| Figure 30: | Psoriasis Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2004-2018 | 60 |
| Figure 31: | Psoriasis Therapeutics Market, Global, Revenue Segmentation (%), 2011 and 2018 | 62 |
| Figure 32: | Psoriasis Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2018 | 63 |
| Figure 33: | Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018 | 64 |
| Figure 34: | Psoriasis Therapeutics Market, Global, Treatment Algorithm | 66 |
| Figure 35: | Psoriasis Therapeutics Market, Drivers and Restraints, 2012 | 67 |
| Figure 36: | Acne Therapeutics Market, Global, Revenue Forecasts (\$bn), 2004-2018 | 69 |
| Figure 37: | Acne Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2004-2018 | 71 |
| Figure 38: | Acne Therapeutics Market, Global, Revenue Segmentation (%), 2011 and 2018 | 72 |
| Figure 39: | Acne Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2018 | 73 |
| Figure 40: | Acne Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018 | 74 |
| Figure 41: | Acne Therapeutics Market, Global, Treatment Algorithm | 76 |
| Figure 42: | Acne Therapeutics Market, Drivers and Restraints, 2012 | 77 |
| Figure 43: | Rosacea Therapeutics Market, Global, Revenue Forecasts (\$bn), 2004-2018 | 79 |
| Figure 44: | Rosacea Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2004-2018 | 80 |
| Figure 45: | Rosacea Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 | 81 |
| Figure 46: | Rosacea Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2018 | 82 |
| Figure 47: | Rosacea Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018 | 83 |
| Figure 48: | Rosacea Therapeutics Market, Global, Treatment Algorithm | 85 |
| Figure 49: | Rosacea Therapeutics Market, Drivers and Restraints, 2012 | 86 |
| Figure 50: | Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts (\$m), 2004-2018 | 87 |
| Figure 51: | Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts by Geography (\$m), 2004-2018 | 89 |
| Figure 52: | Atopic Dermatitis Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 | 90 |

| | |
|---|-----|
| Figure 53: Atopic Dermatitis Therapeutics Market, Global, Annual Cost of Treatment (\$), 2004-2018..... | 91 |
| Figure 54: Atopic Dermatitis Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018..... | 92 |
| Figure 55: Atopic Dermatitis Therapeutics Market, Global, Treatment Algorithm..... | 94 |
| Figure 56: Atopic Dermatitis Therapeutics Market, Drivers and Barriers, 2012..... | 95 |
| Figure 57: Dermatology Therapeutics Market to 2018, Drivers and Restraints, India, 2012..... | 104 |
| Figure 58: Dermatology Therapeutics Market, R&D Pipeline by Indication (%), 2012..... | 109 |
| Figure 59: Dermatology Therapeutics Market, Global, R&D Pipeline by Phase (%), 2012 | 110 |
| Figure 60: Dermatology Therapeutics Market, Alopecia, R&D Pipeline by Phase (%), 2012..... | 111 |
| Figure 61: Dermatology Therapeutics Market, Herpes, R&D Pipeline by Phase (%), 2012 | 112 |
| Figure 62: Dermatology Therapeutics Market, Psoriasis, R&D Pipeline by Phase (%), 2012..... | 113 |
| Figure 63: Dermatology Therapeutics Market, Acne Vulgaris, R&D Pipeline by Phase (%), 2012..... | 116 |
| Figure 64: Dermatology Therapeutics Market, Rosacea, R&D Pipeline by Phase (%), 2012..... | 117 |
| Figure 65: Dermatology Therapeutics Market, Atopic Dermatitis, R&D Pipeline by Phase (%), 2012..... | 118 |
| Figure 66: Dermatology Therapeutics Market, Global, Market Share of Top Manufacturers, 2011..... | 130 |
| Figure 67: Dermatology Therapeutics Market, Global, SWOT Analysis, Johnson & Johnson, 2012..... | 135 |
| Figure 68: Dermatology Therapeutics Market, Global, SWOT Analysis, Amgen, 2012 | 136 |
| Figure 69: Dermatology Therapeutics Market, Global, SWOT Analysis, Merck, 2012 | 138 |
| Figure 70: Dermatology Therapeutics Market, Global, SWOT Analysis, Abbott Laboratories, 2012..... | 140 |
| Figure 71: Dermatology Therapeutics Market, Global, SWOT Analysis, Pfizer, 2012..... | 142 |
| Figure 72: Dermatology Therapeutics Market, Global, SWOT Analysis, GlaxoSmithKline, 2012 | 144 |
| Figure 73: Dermatology Therapeutics Market, Global, SWOT Analysis, Novartis AG, 2012..... | 146 |
| Figure 74: Dermatology Therapeutics Market, Global, SWOT Analysis, Medicis, 2012 | 147 |
| Figure 75: Dermatology Therapeutics Market, Global, SWOT Analysis, Galderma, 2012 | 150 |
| Figure 76: Dermatological Disorders Therapeutics Market, Global, Mergers and Acquisitions by Indication (%), 2009-2012 | 151 |
| Figure 77: Dermatological Disorders Therapeutics Market, Mergers and Acquisitions by Year, 2009-2012 | 152 |
| Figure 78: Dermatological Disorders Therapeutics Market, Mergers and Acquisitions by Type (%), 2009- 2012 | 153 |
| Figure 79: Dermatological Disorders Therapeutics Market, Mergers and Acquisitions by Value (%), 2009- 2012 | 153 |
| Figure 80: Dermatology Therapeutics Market, Mergers and Acquisitions by Geography (%), 2009-2012..... | 154 |
| Figure 81: Dermatology Therapeutics Market, Global, Licensing Agreements by Indication, 2009-2012..... | 156 |
| Figure 82: Dermatology Therapeutics Market, Global, Licensing Agreements by Year, 2009-2012 | 157 |
| Figure 83: Dermatological Disorders Therapeutics Market, Global, Licensing Agreements by Value (%), 2009-2012 | 158 |
| Figure 84: Dermatological Disorders Therapeutics Market, Global, Licensing Agreements by Geography, 2009-2012 | 159 |
| Figure 85: Aesthetic Dermatology, Cosmetic and Reconstructive Plastic Surgery Trends, the US, 2011..... | 161 |
| Figure 86: Aesthetic Dermatology, Cosmetic Plastic Surgery Demographic Trends, the US, 2011 | 162 |
| Figure 87: Aesthetic Dermatology, Drivers and Restraints, 2012..... | 163 |
| Figure 88: GBI Research Market Forecasting Model | 175 |

2 Dermatology Therapeutics Market to 2018 - Introduction


The global dermatology therapeutics market generated approximately \$XX billion in 2011. The market is estimated to reach revenues of \$XX billion by 2018, growing at a Compound Annual Growth Rate (CAGR) of XX% during the forecast period. From 2004, the market grew at a CAGR of XX% to reach \$XX billion in 2011. The report is limited to the following indications: alopecia, herpes (herpes simplex and Herpes Zoster; HZ), psoriasis, acne (also known as acne vulgaris), rosacea, and atopic dermatitis or eczema. The report covers the seven major markets, namely the US, the UK, Spain, Germany, Italy, France and Japan.

SAMPLE

4.2 The US

4.2.1 Revenue

The figure below shows the revenue generated by the US during the historic (2004-2011) and forecast (2011-2018) periods for the dermatology market.



| Table 9: Dermatology Therapeutics Market, the US, Revenue (\$bn), 2004-2011 | | | | | | | | | |
|---|------|------|------|------|------|------|------|------|----------|
| Year | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | CAGR (%) |
| Revenue (\$bn) | | | | | | | | | |

Source: GBI Research's Proprietary Epidemiology and Market Size Database [accessed on: May 29, 2012]; GBI Research's Proprietary Diseases Database [accessed on: May 29, 2012]

| Table 10: Dermatology Therapeutics Market, The US, Revenue Forecasts (\$bn), 2011-2018 | | | | | | | | | |
|--|------|------|------|------|------|------|------|------|----------|
| Year | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | CAGR (%) |
| Revenue (\$bn) | | | | | | | | | |

Source: GBI Research's Proprietary Epidemiology and Market Size Database [accessed on: May 29, 2012]; GBI Research's Proprietary Diseases Database [accessed on: May 29, 2012]


The US dermatology therapeutics market was estimated to be worth \$XX billion in 2011, indicating a growth rate of XX% between 2004 and 2011. The market is estimated to reach revenues of \$XX billion by 2018, growing at a CAGR of XX% from 2011.

The US contributed XX% of the total dermatology therapeutics market in 2011. The US dermatology therapeutics market is quite fragmented and continues to grow at a moderate rate.

5.1.4 Treatment Usage Pattern

The figure below shows the cumulative global population across various parameters during the historic (2004-2011) and forecast (2011-2018) periods for the alopecia therapeutics market.

Figure 19: Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2018



Source: GBI Research's Proprietary Epidemiology and Market Size Database [accessed on: May 31, 2012]

Table 35: Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2004-2011

| Year | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | CAGR (%) |
|------------------------------|------|------|------|------|------|------|------|------|----------|
| Diseased population | | | | | | | | | |
| Treatment-seeking population | | | | | | | | | |
| Diagnosed population | | | | | | | | | |
| Prescription population | | | | | | | | | |

Source: GBI Research's Proprietary Epidemiology and Market Size Database [accessed on: May 31, 2012]

Table 36: Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2011-2018


| Year | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | CAGR (%) |
|------------------------------|------|------|------|------|------|------|------|------|----------|
| Diseased population | | | | | | | | | |
| Treatment-seeking population | | | | | | | | | |
| Diagnosed population | | | | | | | | | |
| Prescription population | | | | | | | | | |

Source: GBI Research's Proprietary Epidemiology and Market Size Database [accessed on: May 31, 2012]

5.3.2.2 Branded Versus Generics

The figure below represents the current (2011) and forecast (2018) market shares captured by branded and generic drugs in the psoriasis therapeutics market.

Figure 31: Psoriasis Therapeutics Market, Global, Revenue Segmentation (%), 2011 and 2018




Source: GBI Research's Proprietary Products Database [accessed on: May 29, 2012]; GBI Research's Proprietary Pipeline Products Database [accessed on: May 7, 2012]

LAS41002, CF101, AIN457, CC-10004, anti-CD6 monoclonal antibody, AMG 827 and MK-3222 are some of the major pipeline molecules for the treatment of psoriasis that will increase the psoriasis therapeutics market during the forecast period by increasing the share of branded molecules to XX%.

7.1.2 Research and Development Pipeline - Herpes

The figure below shows the percentage of molecules across the various stages of development in the herpes R&D pipeline.

Figure 61: Dermatology Therapeutics Market, Herpes, R&D Pipeline by Phase (%), 2012



Source: GBI Research's Proprietary Clinical Trials Database [accessed on: May 7, 2012]; GBI Research's Proprietary Pipeline Products Database [accessed on: May 7, 2012]

The herpes developmental pipeline is weak, with only XX molecules in the various phases of clinical development. However, there are some promising molecules in the Phase III and Phase II stages of development. The present clinical pipeline for HZ therapeutics is weak; XX% of the molecules in the pipeline are being developed for herpes simplex.

11 Dermatology Therapeutics Market to 2017 - Appendix

11.1 Market Definitions

The **global dermatology therapeutics market** includes alopecia, herpes (herpes simplex and herpes zoster), psoriasis, acne, rosacea and atopic dermatitis in the top seven markets: the US, the UK, Germany, France, Spain, Italy and Japan.

GDP - It is defined as the market value of goods and services produced by a country in a year. It is the most widely used measurement of economic output of a country.

Total healthcare expenditure - The sum of expenditure on healthcare and healthcare-related items.

Out-of-pocket healthcare expenditure - Health care costs that are not covered by insurance; such as deductibles, coinsurance, co-payments, and non-covered expenses.

Essential drugs - According to the World Health Organization, essential drugs are 'those that satisfy the primary health care needs of the population'.

Weighted average price - It is determined by assigning a weight (number) to each quantity to be averaged. The weight assigned is based on the relative importance of each quantity.

Ceiling prices - The maximum price, set by law, at which a manufacturer can sell its products.

Wholesale price index - It measures and tracks the alterations in product prices before reaching the retail level.

11.2 Abbreviations

| | |
|----------------|---|
| ACT - | Annual Cost of Treatment |
| APL - | Acute Promyelocytic Leukemia |
| ASAPS - | American Society of Aesthetic Plastic Surgery |
| AWP - | Average Wholesale Price |
| CAGR - | Compound Annual Growth Rate |
| cAMP - | Cyclic Adenosine Monophosphate |
| CIS - | Commonwealth of Independent States |
| COX - | Cyclooxygenase |
| DHT - | Dihydrotestosterone |
| DNA - | Deoxyribonucleic Acid |
| DPCO - | Drugs (Price Control) Order |
| ETR - | Erythematotelangiectatic Rosacea |
| FDA - | Food and Drug Administration |
| GDP - | Gross Domestic Product |
| HCT - | Hematopoietic Cell Transplantation |
| HIV - | Human Immunodeficiency Virus |
| HSV - | Herpes Simplex Virus |
| HZ - | Herpes Zoster |
| IL - | Interleukin |
| IND - | Investigational New Drug |
| IPA - | Indian Pharmaceutical Alliance |
| ISGA - | Investigator's Static Global Assessment |

| | |
|----------------|--|
| ISHRS | - International Society of Hair Restoration Surgery |
| JAK | - Janus Kinase |
| MAA | - Marketing Authorization Application |
| MPB | - Male Pattern Baldness |
| MRSA | - Methicillin-Resistant <i>Staphylococcus aureus</i> |
| NASHA | - Non-Animal Stabilized Hyaluronic Acid |
| NDA | - New Drug Application |
| NDRC | - National Development and Reform Commission |
| NLEM | - National List of Essential Medicines |
| NPPP | - National Pharmaceutical Pricing Policy |
| NSAID | - Non-Steroidal Anti-Inflammatory Drug |
| OPT | - Oral Psoriasis Treatment |
| OTC | - Over the Counter |
| PASI | - Psoriasis Area Severity Index |
| PBS | - Pharmaceutical Benefits Scheme |
| PCI | - Planning Commission of India |
| PDT | - Photodynamic Therapy/Treatment |
| PGA | - Physician's Global Assessment |
| PHN | - Postherpetic Neuralgia |
| PPACA | - Patient Protection and Affordable Care Act |
| PUVA | - Psoralen and Ultraviolet A |
| R&D | - Research and Development |
| RXR | - Retinoid X Receptor |
| RAR | - Retinoic Acid Receptor |
| RNA | - Ribonucleic Acid |
| SFDA | - State Food and Drug Administration |
| TNF | - Tumor Necrosis Factor |
| TNFR | - Tumor Necrosis Factor Receptor |
| UVB | - ultraviolet B |
| VZV | - Varicella-Zoster Virus |
| WAP | - Weighted Average Price |
| WHO | - World Health Organization |
| WPI | - Wholesale Price Index |

11.3 Bibliography

- Acne Foundation (2012). Acne Resources. Available from: http://www.acnefoundation.com/Articles/Acne_Care.php. [Accessed on May 18, 2012].
- American Academy of Family Physician (2000). Topical therapy for acne. Available from: <http://www.aafp.org/afp/2000/0115/p357.html> [Accessed in June 4, 2012].
- American Academy of Family Physician (2009). Treatment options for rosacea. Available from: <http://www.aafp.org/afp/2009/0901/p461.html> [Accessed in June 4, 2012].
- American Society of Aesthetic Plastic Surgery (2011a). Report of the 2010 Plastic Surgery Statistics. Available from: <http://www.google.co.in/url?sa=t&rct=j&q=Breast+augmentation+continues+to+be+the+top+cosmetic+c+surgical+procedure+and+has+held+the+title+since+2006&source=web&cd=1&ved=0CCMQFjAA&url=http%3A%2F%2Fwww.plasticsurgery.org%2FDocuments%2Fnews-resources%2Fstatistics%2F2010-statistics%2FTop-Level%2F2010-US-cosmetic-reconstructive-plastic-surgery-minimally-invasive-statistics2.pdf&ei=WvxbUMujHMXKrAfWkICQAQ&usq=AFQjCNHxxKIMVKtT9sFgHACRtNjRqLzJg>. [Accessed in July 19, 2012].
- American Society of Aesthetic Plastic Surgery (2011b). Cosmetic Plastic Surgery Procedures Performed in 2011. Available from: <http://www.plasticsurgery.org/News-and-Resources/Press-Release-Archives/2012-Press-Release-Archives/138-Million-Cosmetic-Plastic-Surgery-Procedures-Performed-in-2011.html>. [Accessed in July 19, 2012].
- American Society of Aesthetic Plastic Surgery (2011c). 2011 Plastic Surgery Procedural Statistics. Available from: <http://www.plasticsurgery.org/news-and-resources/2011-statistics-.html>. [Accessed in July 19, 2012].
- Astellas Pharma (2012). Annual Report 2011. Available from: http://www.astellas.com/en/ir/library/pdf/annual2011_en.pdf [Accessed in May 11, 2012].
- Augustin M, et al. (2012). Processes of psoriasis health care in Germany - long-term analysis of data from the statutory health insurances. *Journal of the German Society of Dermatology*; 10: 648-655.
- Australian Government Department of Health and Ageing (2012). Pharmaceutical Benefits Scheme. Available from: <http://www.pbs.gov.au/browse/body-system?depth=1&codes=d>. [Accessed in June 7, 2012].
- Australian Herpes Management Forum (2012). Drivers and Restraints. Available from: <http://www.ahmf.com.au/> [Accessed in May 14, 2012].
- Bhosle M, et al. (2006). Quality of life in patients with psoriasis. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1501000/> [Accessed in May 22, 2012].
- Biocon (2012). Annual Report 2011. Available from: http://www.biocon.com/biocon_invrelation_annual_reports.asp?subLink=finance [Accessed in May 23, 2012].
- Ceatus Media Group (2012). Breast augmentation costs. Available from: <http://www.breastimplants4you.com/cost.htm> [Accessed in June 12, 2012].
- Center for Aesthetic Dermatology (2011). Drivers and Restraints. Available from: http://www.aestheticdermatology.com/botox-fillers.php#tissue_fillers [Accessed in June 20, 2012].
- Chandran V and Raychaudhuri S (2010). Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. *Journal of Autoimmunity*; 34:314-321
- Dogra S and Yadav S (2010). Psoriasis in India: Prevalence and pattern. *Indian Journal of Dermatology, Venereology and Leprology*; 76:595-601.
- Galderma (2009). Practical approaches to patient management. Available from: <http://www.the-dermatologist.com/supplements/pdf/winterhawaiiiderm.pdf> [Accessed in June 13, 2012].
- GBI Research (2012). Dermatology Therapeutics Market to 2017, GBIHC151MR.

- GSK (2012). Annual Report 2011. Available from: <http://www.gsk.com/investors/index.htm> [Accessed in May 16, 2012].
- Hair Foundation (2011). Drivers and Restraints. Available from: <http://www.hairfoundation.org/> [Accessed in May 29, 2012].
- Herpes Viruses Association (2012). Drivers and Restraints. Available from: <http://www.herples.org.uk/> [Accessed in May 18, 2012].
- Ipca (2012). Annual Report 2011. Available from: http://www.ipcalabs.com/pdf/finance/annual_report_2011_12.pdf [Accessed in May 25, 2012].
- J&J (2012). Annual Report 2011. Available from: <http://www.investor.jnj.com/annual-reports.cfm> [Accessed in May 4, 2012].
- Mechcatie E (2001). Accutane granted 6-month extension of patent. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791318/> [Accessed in May 22, 2012].
- Meda (2012). Annual Report 2011. Available from: <http://www.meda.se/financial-information/> [Accessed in May 4, 2012].
- Medicis (2012). Annual Report 2011. Available from: <http://www.medicis.com/company/annual.asp> [Accessed in May 11, 2012].
- Medscape (2012). Alopecia areata treatment and management. Available from: <http://emedicine.medscape.com/article/1069931-treatment>. [Accessed in May 14, 2012].
- Merck (2012). Annual Report 2011. Available from: <http://www.merck.com/investors/financials/home.html> [Accessed in May 28, 2012].
- Ministry of Health and Family Welfare (2011). National List of Essential Medicines of India (2011). Available from: <http://www.mohfw.nic.in/WriteReadData/l892s/4767463099list.pdf> [Accessed in May 21, 2012].
- National Alopecia Areata Foundation (2011). Drivers and Restraints. Available from: <http://www.naaf.org/site/PageServer> [Accessed in May 16, 2012].
- National Eczema Association (2012). Drivers and Restraints. Available from: <http://www.nationaleczema.org/> [Accessed in May 10, 2012].
- National Psoriasis Foundation (2009). Treatment algorithms and management. Available from: <http://www.psoriasis.org/document.doc?id=354> [Accessed in May 23, 2012].
- National Psoriasis Foundation (2012). Drivers and Restraints. Available from: <http://www.psoriasis.org/i-have-psoriasis> [Accessed in June 21, 2012].
- National Rosacea Society (2012). Drivers and Restraints. Available from: <http://www.rosacea.org/index.php> [Accessed in May 24, 2012].
- National Shingles Foundation (2012). Drivers and Restraints. Available from: <http://www.vzvfoundation.org/> [Accessed in May 14, 2012].
- Novartis (2012). Annual Report 2011. Available from: <http://www.novartis.com/investors/financialresults/annual-results-2011.shtml> [Accessed in May 22, 2012].
- Pascoe D (2012). Patents expire for Lipitor and Zyprexa, Oracea small fry. Available from: <http://rosacea-support.org/patents-expire-for-liptor-and-zyprexa-oracea-small-fry.html> [Accessed in May 30, 2012].
- Pharma China (2010). Review of new Chinese pharmaceutical/healthcare regulations in 2010. Available from: <http://www.pharmachinaonline.com/admin/eWebEditor/UploadFile/201117145351421.pdf> [Accessed in June 19, 2012].
- Psoriasis Association (2012a). News and Events. Available from: <https://www.psoriasis-association.org.uk/news-and-views/view/dovonex-cream-discontinued>. [Accessed in June 5, 2012].

- Psoriasis Association (2012b). Drivers and Restraints. Available from: <https://www.psoriasis-association.org.uk/pages/view/about-psoriasis> [Accessed in June 20, 2012].
- Saeki H, et al. (2009). Guidelines for management of atopic dermatitis. *The Journal of Dermatology*; 36(10): 563-577
- Thomas K, et al. (2009). The cost-effectiveness of rosacea treatments. *Journal of Dermatological Treatment*; 20(2):72-5.
- Thomas K, et al. (2011). Implementing US-style anti-fraud laws in the Australian pharmaceutical and health care industries. *The Medical Journal of Australia*; 194 (9): 474-478
- Warner Chilcott (2012). Annual Report 2011. Available from: <http://ir.wcrx.com/annuals.cfm>. [Accessed in May 21, 2012].

11.4 Research Methodology

GBI Research's dedicated research and analysis teams consist of experienced professionals with a pedigree in marketing, market research, consulting backgrounds in the medical devices industry, and advanced statistical expertise.

GBI Research adheres to the codes of practice of the Market Research Society (www.mrs.org.uk) and the Strategic and Competitive Intelligence Professionals (www.scip.org).

All GBI Research databases are continuously updated and revised.

11.4.1 Coverage

The objective of updating GBI Research's coverage is to ensure that it represents the most up-to-date vision of the industry possible.

Changes to the industry taxonomy are decided on the basis of extensive research of company, association and competitor sources.

Company coverage is based on three key factors: market capitalization, revenues, and media attention/innovation/market potential.

- An exhaustive search of 56 member exchanges is conducted, and companies are prioritized on the basis of their market capitalization;
- The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage; and,
- Companies which are making the news, or which are of particular interest due to their innovative approach, are prioritized.

GBI Research aims to cover all major news events and deals in the medical industry, with its databases updated on a daily basis.

The coverage is further streamlined and strengthened with additional inputs from GBI Research's expert panel (see below).

11.4.2 Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market.

The secondary research sources that are typically referred to include, but are not limited to:

- Company websites, annual reports, financial reports, broker reports, investor presentations and US Securities and Exchanges Commission (SEC) filings.
- Industry trade journals, scientific journals and other technical literature.
- Internal and external proprietary databases.
- Relevant patent and regulatory databases.
- National government documents, statistical databases and market reports.

- Procedure registries.
- News articles, press releases and webcasts specific to the companies operating in the market.

11.4.3 Primary Research

GBI Research conducts hundreds of primary interviews each year with industry participants and commentators, in order to validate its data and analysis. A typical research interview fulfills the following functions:

- It provides first-hand information on the market size, market trends, growth trends, competitive landscape, future outlook, etc.
- Helps in validating and strengthening the secondary research findings; and
- Further develops the analysis team's expertise and market understanding.

Primary research involves email interactions, telephone interviews, and face-to-face interviews for each market, category, segment and sub-segment across geographies.

The participants who typically take part in such a process include, but are not limited to:

- Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers.
- Hospital stores, laboratories, pharmacies, distributors and paramedics.
- Outside experts: Investment bankers, valuation experts, research analysts specializing in specific medical equipment markets; and
- Key Opinion Leaders: Physicians and surgeons specializing in different therapeutic areas corresponding to different kinds of medical equipment.

The report consists of the following four major sections:

Geographic Landscape

Therapeutic Landscape

Pipeline Analysis

Competitive Analysis

11.5 Therapeutic Landscape

The revenues for each indication, by geography, are arrived at by utilizing the GBI Research market forecasting model. The global revenues for each indication are a summarized value of the revenues of all seven regions.

The annual cost of therapy for each indication is arrived at by considering the cost of the drugs, dosage of the drugs, and the duration of the therapy.

The generic share of the market for each indication is obtained by calculating the prescription share for generic drugs and the respective cost of treatment.

The treatment usage pattern, which includes quantitative data on diseased population, treatment-seeking population, diagnosed population and treated population for an indication, is arrived at by referring to various sources, as described below.

The marketed drugs section contains an overview of the drugs, their mechanism of action, efficacy and safety issues related to the drugs. The drugs profiled in this section are chosen based on estimated revenues and their mechanism of action.

GBI Research uses the epidemiology-based treatment flow model to forecast the market size for therapeutic indications.

11.5.1.1 Epidemiology-based Forecasting

The forecasting model used at GBI Research makes use of epidemiology data gathered from research publications and primary interviews with physicians to represent the treatment flow patterns for individual diseases and therapies. The market for any disease segment is directly proportional to the volume of units sold and the price per unit.

$\text{Sales} = \text{Volume of units sold} \times \text{Price per unit}$

The volume of units sold is calculated based on the average dosage regimen for that disease, the duration of treatment, and the number of patients who are prescribed drug treatment (the prescription population). The prescription population is calculated as a % of the population diagnosed with a disease (the diagnosis population). The diagnosis population is the population diagnosed with a disease expressed as a % of the population that is seeking treatment (the treatment-seeking population). The prevalence of a disease (diseased population) is the % of the total population who suffer from a disease/condition.

Data on treatment seeking rate, diagnosis rate and prescription rate, if unavailable from research publications, are gathered from interviews with physicians and are used to estimate the patient volumes for the disease under consideration. Therapy uptake and compliance data are fitted in the forecasting model to account for patient switching and compliance behavior.

To account for differences in patient affordability of drugs across various geographies, macroeconomic data such as inflation and GDP, and healthcare indicators such as healthcare spending, insurance coverage and average income per individual, are used.

Annual cost of treatment is calculated using product purchase frequency and the average price of the therapy. Product purchase frequency is calculated from the dosage data available for the therapies, and drug prices are gathered from public sources.

The epidemiology-based forecasting model uses a bottom-up methodology, and makes use of estimations in the absence of data from research publications. Such estimations may result in a final market value that is different from the actual value. To correct this 'gap', the forecasting model uses triangulation, with the help of base year sales data (from company annual reports, internal and external databases) and sales estimations.

Analogous Forecasting Methodology

The analogous forecasting methodology is used to account for the introduction of new products, patent expiries of branded products, and the subsequent introduction of generics. Historic data for new product launches and generics penetration are used to arrive at robust forecasts. The increase or decrease of prevalence rates, treatment seeking rate, diagnosis rate and prescription rate are fitted into the forecasting model to estimate the market growth rate.

The proprietary model enables GBI Research to account for the impact of individual drivers and restraints in the growth of the market. The year of impact and the extent of impact are quantified in the forecasting model to provide close-to-accurate data sets.

Diseased Population

The diseased population for any indication is the prevalence. The prevalence rates are usually obtained from various journals, online publications, sources such as the World Health Organization (WHO) or associations and foundation websites for that particular disease.

Treatment-Seeking Population

The treatment-seeking population is always calculated as a % of prevalence. The number denotes the actual number of patients who are reported as going to hospitals to get diagnosed for a disease. The treatment-seeking population is primarily driven by the onset of symptoms, patient awareness, and the severity of the disease.

Diagnosis Population

Out of the patients who undergo diagnostic tests to confirm a disease, only a few people get diagnosed with the disease. This number as a % of the treatment-seeking population is the diagnosis rate. The diagnosis population is primarily driven by the sensitivity of the diagnostic tests, state-of-the-art technology, patient access to these diagnostic tests, and cost of the diagnostic tests.

Prescription Population

For any disease, multiple treatment options exist. For example, in cancer treatment various treatment options such as surgery, radiation therapy and drug therapy are available. The prescription population is defined as the number of patients who are prescribed drug therapy. This is calculated as a % of the diagnosis population. The prescription population is primarily driven by the age at which the disease is diagnosed, the disease stage, patient health and the cost of drug treatment.

11.5.2 Market Size by Geography

The treatment usage pattern and annual cost of treatment in each country has been factored in while deriving the individual country market size.

Forecasting Model for Therapeutic Areas

Figure 88: GBI Research Market Forecasting Model

| GBI Research Market Sizing Model | | |
|--|------|------------------|
| Disease Population | | |
| General Population | | 743,535,048 |
| Qualifying condition 1 (Age/Sex/Occupation etc) | | |
| Qualifying condition 2 (Age/Sex/Occupation etc) | | |
| Prevalence tissue valve disease | 0.2% | 1,784,484 |
| Qualifying condition (complication, severity) | | |
| DISEASED POPULATION | | 1,784,484 |
| Treatment Flow Patterns | | |
| Treatment Seeking Rate (Symptoms/Dis Awareness) | 89% | 1,588,191 |
| Diagnosis Rate (Clinical and Diagnostic Tests) | 75% | 1,191,143 |
| Prescription Rate (Physician Perception, Treatment Effectiveness) | | |
| Tissue Valve | 70% | 833,800 |
| Other Treatments for Valve (Surg/Med/None) | | - |
| Fulfillment | | |
| Availability | NA | |
| Willingness to Use (Patient Perceptions) | NA | |
| Ready to Use (Surgery eligibility, Reuse etc) | NA | |
| Affordability at Price | | |
| HE as % of GDP spend | | |
| Average Income (per individual) | | |
| Patient Out-of-pocket Budget (Annual) | | |
| Budget allocation to one-time surgery | | |
| Budget allocation to other health needs | | |
| Average Payor Coverage | | |
| Patient Liability | | |
| Target Price (@20% pat liab) | | |
| ASP for Cost of Therapy | | |
| TOTAL PATIENT VOLUMES | | |
| Product Purchase Frequency | 1 | |
| TOTAL UNIT VOLUMES | | |
| Pricing per Unit | | |
| Inflation | | |
| Price Decrease due to competition | | |
| Market Value | | |

Source: GBI Research

The above figure represents a typical forecasting model constructed by GBI Research. As discussed previously, the model is built on the treatment flow patterns. The model starts with the general population, then diseased population as a % of general population, and then follows the treatment-seeking population as a % of the diseased population, and the diagnosed population as a % of the treatment-seeking population. Finally, the total volume of units sold is calculated by multiplying the treated population by the average dosage per year per patient.

Articles are used from research journals and agency publications, such as National Alopecia Areata Foundation, Hair Foundation, Australian Herpes Management Forum, Herpes Viruses Association, National Shingles Foundation, Psoriasis Association, National Psoriasis Foundation, American Academy of Family Physician, National Rosacea Society, National Eczema Association, Ministry of Health and Family Welfare, Pharma China. The marketed drugs section is constructed from company websites and internal databases.

11.6 Geographical Landscape

GBI Research analyzes seven major geographies, namely, the US, the top five countries in Europe (the UK, Germany, France, Spain and Italy), and Japan. The total market size for each country is provided, which is the summarized value of the market sizes of all the indications for that particular country.

11.7 Pipeline Analysis

This section provides a list of molecules at different stages in the pipeline for various indications. The list is sourced from internal databases and validated for the accuracy of phase and mechanism of action at clinicaltrials.gov and company websites. The section also includes a list of promising molecules, which is narrowed down based on the results of the clinical trials at various stages and the novelty of the mechanism of action.

11.8 Competitive Landscape

Profiles of leading players are provided, along with an overview of key products marketed by the companies for various indications. An analysis of strengths, weaknesses, opportunities and threats of each company with respect to various indications is also listed.

GBI Research aims to cover all major MERGERS AND ACQUISITIONS, licensing deals and co-development deals related to the market. This section is sourced from the companies' websites and internal databases.

11.8.1 Expert Panel Validation

GBI Research uses a panel of experts to cross-verify its databases and forecasts.

GBI Research's expert panel comprises marketing managers, product specialists, international sales managers from medical device companies, academics from research universities, and key opinion leaders from hospitals.

Historic data and forecasts are relayed to GBI Research's expert panel for feedback and adjusted in accordance with their feedback.

11.10 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research.

SAMPLE